(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 239.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.59%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.81%.
Ocugen's revenue in 2026 is $4,465,000.On average, 9 Wall Street analysts forecast OCGN's revenue for 2026 to be $1,433,640,060, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $2,179,742,231. On average, 7 Wall Street analysts forecast OCGN's revenue for 2027 to be $3,804,647,140, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $12,581,164,778.
In 2028, OCGN is forecast to generate $72,227,023,196 in revenue, with the lowest revenue forecast at $4,578,169,581 and the highest revenue forecast at $144,504,824,671.